iAP Biomarker Detection for Necrotizing Enterocolitis Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Necrotizing enterocolitis (NEC) in pre-term infants is difficult to diagnose and manage due to nonspecific symptomatology and rapid deterioration, leading to high mortality and long-term morbidity, with existing diagnostic methods relying on radiographic evidence in advanced stages.
Innovation Solution
A method using a Markov model with a two-state transition matrix and propensity values based on intestinal Alkaline Phosphatase (iAP) activity to estimate the probability of NEC progression, involving a biological sample analysis with an agent binding to iAP and subsequent immunoassay to detect biomarkers for early and advanced disease stages.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If radiographic evidence is used to diagnose NEC, then diagnosis can be made in advanced stage of disease, but early detection is not possible and mortality remains high
Solution Approach 1:
The patent applies preliminary action by measuring iAP activity and protein levels in stool samples to detect NEC risk before radiographic signs appear. The method identifies biochemical changes in the early stages of disease progression, enabling intervention before advanced necrotizing enterocolitis develops. This shifts diagnosis from reactive (after radiographic evidence) to proactive (before clinical deterioration).
Solution Approach 2:
The patent replaces the mechanical/radiographic diagnostic system with a biochemical detection system. Instead of using X-ray imaging to detect pneumatosis intestinalis in advanced stages, the method uses enzymatic activity assays and immunoassays to detect iAP changes that precede radiographic evidence, substituting a more sensitive biochemical detection mechanism for the less sensitive radiographic approach.
2Measurement precision
If iAP activity and protein level analysis is performed, then early NEC risk can be identified, but additional testing complexity is introduced
Solution Approach 1:
The patent applies universality by using a single biomarker (iAP) that serves multiple diagnostic functions. The same iAP measurement system detects both early risk (through activity assays) and progression status (through protein level immunoassays), eliminating the need for multiple separate diagnostic tests. This multi-functional approach increases detection accuracy without proportionally increasing system complexity.
Solution Approach 2:
The patent uses parameter changes by monitoring different aspects of the same biomarker (iAP) at different stages. Early detection relies on measuring iAP enzymatic activity parameters, while progression detection uses iAP protein level parameters. This allows a single diagnostic system to detect disease at multiple stages by changing which parameter of the biomarker is measured, rather than requiring entirely different tests.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables early detection and differentiation between early and advanced stages of NEC, facilitating timely intervention and potentially reducing mortality and morbidity by identifying increased NEC risk through iAP activity and protein level analysis.
Implementation Method 1
incubating a biological sample from a subject with an agent that binds intestinal alkaline phosphatase (iAP), detecting in the sample iAP-bound agent, and detecting and/or measuring in the sample the amount or activity of iAP in sample
Data Source
AI summary
This invention comprises compositions and methods to determine the prognosis of necrotizing enterocolitis.